Document:

Exhibit
10.20

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR REGISTERED
OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS SUCH
SALE, TRANSFER, PLEDGE OR HYPOTHECATION IS IN ACCORDANCE WITH SUCH ACT AND APPLICABLE STATE SECURITIES LAWS.

 

Warrant
No. ____

 

No.
of Shares of Common Stock: 100,000

 

SERIES
C

 

WARRANT

to
Purchase Common Stock of

 

Textmunication
Holdings, Inc. 

a Nevada Corporation

 

This
Warrant certifies that Michael O’Conner (“Purchaser”), is entitled to purchase from Textmunication Holdings,
Inc., a Nevada corporation (the “Company”), 100,000 shares of Common Stock (or any portion thereof) at an exercise
price of $0.125 per share of Common Stock, all on the terms and conditions hereinafter provided.

 

Section
1. Certain Definitions. As used in this Warrant, unless the context otherwise requires:

 

“Articles”
shall mean the Articles of Incorporation of the Company, as in effect from time to time.

 

“Common
Stock” shall mean the Company’s authorized common stock, $0.001 par value per share.

 

“Exercise
Price” shall mean the exercise price per share of Common Stock set forth above, as adjusted from time to time pursuant
to Section 3 hereof.

 

“Securities
Act” shall mean the Securities Act of 1933, as amended.

 

“Warrant”
shall mean this Warrant and all additional or new warrants issued upon division or combination of, or in substitution for, this
Warrant. All such additional or new warrants shall at all times be identical as to terms and conditions and date, except as to
the number of shares of Common Stock for which they may be exercised.

 

“Warrant
Stock” shall mean the shares of Common Stock purchasable by the holder of this Warrant upon the exercise of such Warrant.

 

“Warrantholder”
shall mean the Purchaser, as the initial holder of this Warrant, and its nominees, successors or assigns, including any subsequent
holder of this Warrant to whom it has been legally transferred.

 

Section
2. Exercise of Warrant.

 

(a)
At any time after the date hereof, the Purchaser may at any time and from time to time exercise this Warrant, in whole or in part.
This Warrant expires one year from the date hereof.

 

    	 

    	 

    

 

(b)  
(i) The Warrantholder shall exercise this Warrant by means of delivering to the Company at its office identified in Section 14
hereof (i) a written notice of exercise, including the number of shares of Warrant Stock to be delivered pursuant to such exercise,
(ii) this Warrant and (iii) payment equal to the Exercise Price in accordance with Section 2(b)(ii). In the event that any exercise
shall not be for all shares of Warrant Stock purchasable hereunder, the Company shall deliver to the Warrantholder a new Warrant
registered in the name of the Warrantholder, of like tenor to this Warrant and for the remaining shares of Warrant Stock purchasable
hereunder, within ten (10) days of any such exercise. Such notice of exercise shall be in the Subscription Form set out at the
end of this Warrant.

 

(ii)
The Warrantholder may elect to pay the Exercise Price to the Company either by cash, certified check or wire transfer.

 

(c)   
Upon exercise of this Warrant and delivery of the Subscription Form with proper payment relating thereto, the Company shall cause
to be executed and delivered to the Warrantholder a certificate or certificates representing the aggregate number of fully-paid
and nonassessable shares of Common Stock issuable upon such exercise.

 

(d)  
The stock certificate or certificates for Warrant Stock to be delivered in accordance with this Section 2 shall be in such denominations
as may be specified in said notice of exercise and shall be registered in the name of the Warrantholder or such other name or
names as shall be designated in said notice. Such certificate or certificates shall be deemed to have been issued and the Warrantholder
or any other person so designated to be named therein shall be deemed to have become the holder of record of such shares, including
to the extent permitted by law the right to vote such shares or to consent or to receive notice as stockholders, as of the time
said notice is delivered to the Company as aforesaid.

 

(e)   
The Company shall pay all expenses payable in connection with the preparation, issue and delivery of stock certificates under
this Section 2, resulting from the exercise of the Warrant and the issuance of Warrant Stock hereunder.

 

(f)   
All shares of Warrant Stock issuable upon the exercise of this Warrant in accordance with the terms hereof shall be validly issued,
fully paid and nonassessable, and free from all liens and other encumbrances thereon, other than liens or other encumbrances created
by the Warrantholder.

 

(g)   
In no event shall any fractional share of Common Stock of the Company be issued upon any exercise of this Warrant. If, upon any
exercise of this Warrant, the Warrantholder would, except as provided in this paragraph, be entitled to receive a fractional share
of Common Stock, then the Company shall deliver in cash to such holder an amount equal to such fractional interest.

 

Section
3. Adjustment of Exercise Price and Warrant Stock.

 

(a)
If, at any time prior to the Expiration Date, the number of outstanding shares of Common Stock is (i) increased by a stock dividend
payable in shares of Common Stock or by a subdivision or split-up of shares of Common Stock, or (ii) decreased by a combination
of shares of Common Stock, then, following the record date fixed for the determination of holders of Common Stock entitled to
receive the benefits of such stock dividend, subdivision, split-up, or combination, the Exercise Price shall be adjusted to a
new amount equal to the product of (I) the Exercise Price in effect on such record date and (II) the quotient obtained by dividing
(x) the number of shares of Common Stock outstanding on such record date (without giving effect to the event referred to in the
foregoing clause (i) or (ii)), by (y) the number of shares of Common Stock which would be outstanding immediately after the event
referred to in the foregoing clause (i) or (ii), if such event had occurred immediately following such record date.

 

    	2

    	 

    

 

(b)
Upon each adjustment of the Exercise Price as provided in Section 3 (a), the Warrantholder shall thereafter be entitled to subscribe
for and purchase, at the Exercise Price resulting from such adjustment, the number of shares of Warrant Stock equal to the product
of (i) the number of shares of Warrant Stock existing prior to such adjustment and (ii) the quotient obtained by dividing (I)
the Exercise Price existing prior to such adjustment by (II) the new Exercise Price resulting from such adjustment.

 

Section
4. Division and Combination. This Warrant may be divided or combined with other Warrants upon presentation at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Warrantholder or its agent or attorney. The Company shall pay all expenses in connection with the preparation, issue
and delivery of Warrants under this Section 4, including any transfer taxes resulting from the division or combination hereunder.
The Company agrees to maintain at its aforesaid office books for the registration of the Warrants.

 

Section
5. Reclassification, Etc. In case of any reclassification or change of the outstanding Common of the Company (other than
as a result of a subdivision, combination or stock dividend), or in case of any consolidation of the Company with, or merger of
the Company into, another corporation or other business organization (other than a consolidation or merger in which the Company
is the continuing corporation and which does not result in any reclassification or change of the outstanding Common Stock of the
Company) at any time prior to the Expiration Date, then, as a condition of such reclassification, reorganization, change, consolidation
or merger, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor shall
be delivered to the Warrantholder, so that the Warrantholder shall have the right prior to the Expiration Date to purchase, at
a total price not to exceed that payable upon the exercise of this Warrant, the kind and amount of shares of stock and other securities
and property receivable upon such reclassification, reorganization, change, consolidation or merger by a holder of the number
of shares of Common Stock of the Company which might have been purchased by the Warrantholder immediately prior to such reclassification,
reorganization, change, consolidation or merger, in any such case appropriate provisions shall be made with respect to the rights
and interest of the Warrantholder to the end that the provisions hereof (including provisions for the adjustment of the Exercise
Price and of the number of shares purchasable upon exercise of this Warrant) shall thereafter be applicable in relation to any
shares of stock and other securities and property thereafter deliverable upon exercise hereof.

 

Section
6. Reservation and Authorization of Capital Stock. The Company shall at all times reserve and keep available for issuance
such number of its authorized but unissued shares of Common Stock as will be sufficient to permit the exercise in full of all
outstanding Warrants.

 

Section
7. Stock and Warrant Books. The Company will not at any time, except upon dissolution, liquidation or winding up, close
its stock books or Warrant books so as to result in preventing or delaying the exercise of any Warrant.

 

Section
8. Limitation of Liability. No provisions hereof, in the absence of affirmative action by the Warrantholder to purchase
Warrant Stock hereunder, shall give rise to any liability of the Warrantholder to pay the Exercise Price or as a stockholder of
the Company (whether such liability is asserted by the Company or creditors of the Company).

 

Section
9. Transfer. Subject to compliance with the Securities Act and the applicable rules and regulations promulgated thereunder,
this Warrant and all rights hereunder shall be transferable in whole or in part. Any such transfer shall be made at the office
or agency of the Company at which this Warrant is exercisable, by the registered holder hereof in person or by its duly authorized
attorney, upon surrender of this Warrant together with the assignment hereof properly endorsed, and promptly thereafter a new
warrant shall be issued and delivered by the Company, registered
in the name of the assignee. Until registration of transfer hereof on the books of the Company, the Company may treat the Purchaser
as the owner hereof for all purposes.

 

    	3

    	 

    

 

Section
10. Investment Representations; Restrictions on Transfer of Warrant Stock. Unless a current registration statement under
the Securities Act shall be in effect with respect to the Warrant Stock to be issued upon exercise of this Warrant, the Warrantholder,
by accepting this Warrant, covenants and agrees that, at the time of exercise hereof, and at the time of any proposed transfer
of Warrant Stock acquired upon exercise hereof, such Warrantholder will deliver to the Company a written statement that the securities
acquired by the Warrantholder upon exercise hereof are for the account of the Warrantholder or are being held by the Warrantholder
as trustee, investment manager, investment advisor or as any other fiduciary for the account of the beneficial owner or owners
for investment and are not acquired with a view to, or for sale in connection with, any distribution thereof (or any portion thereof)
and with no present intention (at any such time) of offering and distributing such securities (or any portion thereof).

 

Section
11. Loss, Destruction of Warrant Certificates. Upon receipt of evidence satisfactory to the Company of the loss, theft,
destruction or mutilation of any Warrant and, in the case of any such loss, theft or destruction, upon receipt of indemnity and/or
security satisfactory to the Company or, in the case of any such mutilation, upon surrender and cancellation of such Warrant,
the Company will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Warrant, a new Warrant of like tenor and
representing the right to purchase the same aggregate number of shares of Common Stock.

Section
12. Amendments. The terms of this Warrant may be amended, and the observance of any term herein may be waived, but only
with the written consent of the Company and the Warrantholder.

 

Section
13. Notices Generally. Any notice, request, consent, other communication or delivery pursuant to the provisions hereof
shall be in writing and shall be sent by one of the following means: (i) by registered or certified first class mail, postage
prepaid, return receipt requested; (ii) by facsimile transmission with confirmation of receipt; (iii) by nationally recognized
courier service guaranteeing overnight delivery; or (iv) by personal delivery, and shall be properly addressed to the Warrantholder
at the last known address or facsimile number appearing on the books of the Company, or, except as herein otherwise expressly
provided, to the Company at its principal executive office, or such other address or facsimile number as shall have been furnished
to the party giving or making such notice, demand or delivery.

 

Section
14. Successors and Assigns. This Warrant shall bind and inure to the benefit of and be enforceable by the parties hereto
and their respective permitted successors and assigns.

 

Section
15. Governing Law. In all respects, including all matters of construction, validity and performance, this Warrant and the
obligations arising hereunder shall be governed by, and construed and enforced in accordance with the laws of the State of Nevada.

 

    	4

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be signed in its name by its Chief Executive Officer.

 

	Dated:
    July 7, 2014	 	 
	 	 	 
	 	Textmunication
    Holdings, Inc. 

    a Nevada Corporation
	 	 
	 	By:	/s/
    Wais Asefi
	 	Name:	Wais
    Asefi
	 	Title	Chief
    Executive Officer

 

 

5Purchase and Sale Agreement

 Exhibit 10.1 

PURCHASE AND SALE AGREEMENT 
 THIS
AGREEMENT is made effective as of the 8th day of October, 2014 
 AMONG: 

MYCELL TECHNOLOGIES LLC a corporation existing under the laws of the state of —
whose principle place of business is located at 140 East Ridgewood Avenue, Suite 125, Paramus, NJ 07652; 
 (“Mycell”) 

AND: 
 MCT BEVERAGE COMPANY, LLC, a
corporation existing under the laws of the state of — whose principle place of business is located at 140 East Ridgewood Avenue, Suite 125, Paramus, NJ 07652; 

(“MCT”) 

(Mycell and MCT and jointly and individually referred to herein as the “Vendor”) 

AND: 
 OMEGA BRANDS, INC., a
corporation existing under the laws of the state of Nevada whose principle place of business is located at 5005 Interbay Blvd, Tampa, FL 33611 (the “Purchaser”) 

(the “Purchaser”) 
 WHEREAS:

 A. the Vendor formerly carried on the business of developing, producing, marketing and selling certain branded Omega-3 infused beverages and
nutritional shots under the trade name Omega InfusionTM and related marks, (collectively, the “Omega Infusion Business”); 

B. The Vendor owns and controls all right and title in and to certain proprietary formulas, trade-names, trade-secrets, trademarks, marketing materials, and
internet domains related to the former Omega Infusion Business, including but not limited to those assets listed in Schedule “A” hereto (collectively the “Omega Infusion Assets”). 

C. the Vendor has agreed to sell and assign, and the Purchaser has agreed to purchase, all of Vendor’s right and title in and to the Omega Infusion
Assets of the Vendor; and 
 D. in consideration of the Omega Infusion Assets, the Purchaser has agreed to pay certain royalties to the Vendor, and to enter
in that certain Emulsion Supply and Formulation Services Agreement with Oceans Omega LLC dated concurrently herewith (the “Supply Agreement”), upon the terms and subject to the conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto mutually agree as follows: 

  
 1 

 ARTICLE I 

DEFINITIONS 

Section 1.1 Definitions. For the purposes of this Agreement, the following definitions shall apply: 

 

	 	a.	“Affiliates” mean, with respect to a Person, any other Person which, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such
Person; For purposes of this definition “control” means the right, directly or indirectly (i) to exercise significant influence over another Person’s operating and financial policies or (ii) to direct the management or
policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

  

	 	b.	“Agreement” means this agreement, and all schedules and other documents attached to or referred to in this agreement, and all amendments and supplements, if any, to this agreement;

  

	 	c.	“Closing” means the completion of the Transaction, in accordance with Article IX of this Agreement, at which the Closing Documents shall be exchanged by the Parties, except for those documents or
other items specifically required to be exchanged at a later time; 

  

	 	d.	“Closing Date” shall have the meaning set forth in Section 9.5 of this Agreement; 

  

	 	e.	“Closing Documents” mean the papers, instruments and documents required to be executed and delivered at the Closing pursuant to Article IX of this Agreement; 

 

	 	f.	“Confidential Information” means all information pertaining to the Omega Infusion Assets, 

  

	 	g.	“Effective Date” means the effective date of this Agreement; 

  

	 	h.	“Event of Default” means any default on the part of the Vendor to in respect of its obligations hereunder continuing for twenty (20) days after delivery to the Vendor by or on behalf of the
Purchaser of notice of such default, and unless such default is capable of cure but cannot be cured within such time frame and the Vendor is using reasonable commercial efforts to cure same in a timely fashion; 

 

	 	i.	“Formulae” means any and each of the proprietary beverage mixing formulae formerly or currently marketed under the brand known as “Omega Infusion”, owned or controlled by the Vendor and
set forth on Schedule A.,. Notwithstanding the foregoing, the rights in and to the Formulae granted hereunder shall specifically exclude all right and title and license in and to the proprietary Omega-3 emulsions of Vendor, including without
limitation, the emulsions known as INCON OTEC and LIFE’s DHA OTEC. Each Vendor and the Purchaser agrees that the Purchaser’s access to the Vendor Emulsions shall be governed by the Supply Agreement attached hereto as exhibit C;

  

	 	j.	“Intellectual Property” means all rights and title under copyright or trademark, marketing materials, and all trade-names, designs, Technical Know-How, Patents and other intellectual property
rights of any kind throughout the world, whether registered or not, and all physical embodiments thereof; 

  
 2 

	 	k.	“knowledge” means with respect to the representations and warranties of Vendor that refer to knowledge, to the knowledge of Volker Berl, Bruce Lipshutz and Frank Gallagi. 

 

	 	l.	“Net Proceeds” mean the gross amount received by Purchaser, or its Affiliates, or any of them, on each sale of the applicable Omega Infusion Assets less (i) discounts actually allowed, (ii) credits
for claims, allowances, retroactive price reductions, (iii) duties, transportation and insurance, sales taxes or other governmental charges actually paid in connection with provision of good or services (but excluding what are commonly known as
income taxes and value-added taxes). 

  

	 	m.	“Omega Infusion Assets” mean all assets listed in Schedule “A” hereto; 

  

	 	n.	“Party” or “Parties” mean each or collectively, respectively, the Purchaser and the Vendor; 

 

	 	o.	“Patents” mean all rights under any present or future patents and/or patent applications throughout the world, and shall include (i) any divisional, re-examination or renewal based on the
said patents and /or patent applications, any patents which may issue on, from or as a result of any of the foregoing and any reissue of said patents, (ii) the sole and exclusive right to file, prosecute, maintain, and defend any of the
foregoing which exist on the Effective Date; 

  

	 	p.	“Person” means a natural person or partnership (whether general or limited and whether domestic or foreign), limited liability company, foreign limited liability company, limited duration
company, trust, estate, association, corporation, trust, estate, nominee or any other individual or entity in its own or any representative capacity or other entity. 

 

	 	q.	“Technical Know-How” means all published or unpublished research, development information, technical data, designs, formulas, prototypes, samples, plans, specifications, methods, processes,
systems, trade secrets, empirical data, computer programs and any other information or documentation related to the Formulae and to the other Omega Infusion Assets, whether patentable or unpatentable, and whether in written, machine readable, oral
form or drawing, and which exists at the Effective Date; 

  

	 	r.	“Third Party Intellectual Property” means all proprietary rights which exist at the Effective Date related to the Formulae and the Intellectual Property of the Omega Infusion Assets and not
exclusively owned by or vested in the Vendor, whether under copyright, patent, trademark, trade secret or otherwise; and 

  

	 	s.	“Transaction” means the sale and assignment by the Vendor and the purchase by the Purchaser of the Omega Infusion Assets as provided in this Agreement. 

  
 3 

 ARTICLE II 

SALE AND ASSIGNMENT 

Section 2.1 Sale. Subject to the terms and conditions set forth in this Agreement, the Vendor hereby conveys, transfers and
assigns to the Purchaser, 100% of the Vendor’s right, title and interest in and to Omega Infusion Assets. 
 Section 2.2
Vendor Emulsions. The Purchaser acknowledges and agrees that the Formulae purchased hereunder incorporates the use of Omega-3 emulsions of Vendor known as INCON OTEC and LIFE’s DHA OTEC (the “Vendor Emulsions”).
The Purchaser acknowledges and agrees that nothing in this Agreement is intended to convey, transfer or assign to the Purchaser any right, title or license in or to the Vendor Emulsions, or any other emulsions. 

Section 2.3 Delivery. Upon execution of this Agreement, subject to payment of the purchase price in accordance with
Section 3.1, the Vendor shall promptly deliver to the Purchaser all physical embodiments (including but not limited to electronic copies) of the Omega Infusion Assets not previously delivered to the Purchaser prior to the Effective Date. 

ARTICLE III 
 PURCHASE
PRICE 
 Section 3.1 Purchase Price. In full consideration of all rights, title and interest granted by the Vendor to
the Purchaser hereunder, and in consideration of the Vendor’s representations, warranties and covenants hereunder, the Purchaser agrees to pay to the Vendor the following compensation: 

 

	 	a.	Cash Compensation. $1 - payable by wire or cheque upon execution of this Agreement; 

  

	 	b.	Transaction Based Compensation. In the event of one or more sales, transfers, conveyances or assignments by the Purchaser (or any present or future Affiliate of the Purchaser), directly or indirectly to a
non-controlled entity, in one or a series of transactions, of all or any part of the Omega Infusion Assets that utilize the Vendor emulsions (whether by sale or transfer or conveyance or assignment of rights, assets, equity ownership, merger,
combination, licensing or otherwise), the Purchaser shall pay to the Vendor following the closing of any such transaction(s) fifteen percent (15%) of the net proceeds actually received by and vested in the Purchaser (or any present or future
Affiliate or designee of the Purchaser) in respect of any such transactions (the “Transaction Based Compensation”). Any proceeds from issuance of equity by OBRANDS are specifically excluded from the definition of Transaction Based
Compensation. The Transaction Based Compensation shall be payable as follows: 

 i. 15% of net proceeds
consisting of cash shall be payable within 30 business days following Purchaser’s actual receipt thereof; 
 ii.
15% of net proceeds consisting of non-debt securities (stock, stock purchase warrants, or stock options) shall be payable, at the option of the Purchaser, within 30 days following purchasers actual receipt thereof, by either (A) transfer
and assignment to the Vendor of the Vendor’s pro-rata share of applicable instruments or securities; or (B) by payment of equivalent cash value; 

  
 4 

 iii. 15% of net proceeds consisting of debt instruments (promissory
notes), whether or not convertible into equity, shall be payable, at the Option of the Purchaser by either (A) transfer and assignment to the Vendor of the Vendor’s pro-rata share of applicable instruments or security within 30 days of the
Purchaser’s receipt thereof; or (B) payment or transfer and assignment (as applicable) to the Vendor of the Vendor’s pro-rata share of the proceeds collected upon payment (or securities issued upon conversion) of the applicable debt
instrument, within 30 days of the Purchaser’s receipt thereof; 
 iv. 15% of the value of proceeds consisting of
intellectual, personal (other than securities) or real property shall be payable in cash within 120 days of Purchaser’s receipt thereof. 

For the purposes of Section 3.1 (b) the cash value of equity securities shall be determined (i) where a public market exists for the
securities, with reference to the average closing price of the securities (or applicable underlying securities) during the 20 trading days prior to the date upon which they are received by and vested in the Purchaser; or (ii) where no public
market exists for the securities, with reference to the deemed value of the securities designated in the agreement by which they are acquired by the Purchaser. The cash value of real or personal property shall be determined with reference to the
value of the property designated in the agreement by which it is acquired by the Purchaser. 
  

	 	c.	Notwithstanding the foregoing, the Purchaser shall be entitled to transfer any Omega Infusion Asset to any present or future Affiliate(s) of the Purchaser without liability to the Vendor pursuant to this
Section 3.1 (a), provided, however, (i) that Purchaser and its Affiliate transferee shall provide Vendor within thirty (30) days’ after such transfer, written notice of any transfer, together with information concerning the
transfer in writing in reasonable detail including the consideration thereof, (ii) that as a condition to any transfer(s) by Purchaser, in one or more or a series of transactions, (aa) the Affiliate(s) of Purchaser shall execute and deliver
within 30 days to Vendor and other third party designated by Vendor, a written acknowledgement and irrevocable, unconditional continuing agreement in perpetuity of such Affiliate’s assumption of Purchaser’s obligation to pay Vendor, or
other third party designated by the Vendor, the Transaction Based Compensation and to be bound by the other rights of Vendor set forth herein, and (bb) Purchaser shall provide a written, irrevocable and unconditional continuing guarantee in
perpetuity to Vendor of the Affiliate’s obligation to pay Vendor, or other third party designated by Vendor, of the Transaction Based Compensation, and (iii) any sale, directly or indirectly, in one or a series of transactions, of Control
of Purchaser or of any Affiliate(s) of Purchaser that is or become a transferee of all or any part of the Omega Infusion Assets that utilize Vendors emulsions, shall cause the Transaction Based Compensation to be payable to Vendor, or the designee
of the Vendor, as provided hereinabove in accordance with above section 3.1 (b). The foregoing notice, assumption of payment and guarantee obligations and the audit rights set forth below shall be automatically valid and binding upon on all
subsequent Affiliate transferees, if any, following the initial transfer from the Purchaser to the initial Purchaser Affiliate transferee. 

  
 5 

 In the event any of the Transaction Based Compensation is in the form of an earn-out, license
royalties or similar compensation, then in any such event, (a) Vendor shall be provided by Purchaser and all Purchaser Affiliate Transferees with appropriate periodic (but not less frequently than on a calendar quarterly basis) and timely
information and statements in reasonable detail as to the financial and other terms of the earn-out, license royalties or similar compensation and the calculation of such compensation covered by such information and statement, and (b) Vendor
shall have the right to designate a PCAOB certified accounting firm to review and audit the books and records of the Purchaser and all Purchaser Affiliate transferees of the Omega Infusion Assets each year during normal business hours for as long as
such compensation is payable and for a twelve (12) month period thereafter. Such audits shall be conducted at Vendor’s sole cost and expense, provided that if there is an error or discrepancy in excess of twenty percent (20%) of the
amount due to Vendor, then Purchaser and all Purchaser Affiliate transferees shall promptly pay or reimburse Vendor for all of Vendor’s reasonable and documented out of pocket costs and expenses in conducting such audits. Purchaser and all
Purchaser Affiliate transferee(s) shall provide reasonable cooperation in connection with such audits and promptly respond to all discrepancies as may be claimed by Vendors as a result of such audits. Vendor shall provide the Purchaser (or the
Purchaser’s Affiliate Transferees, as applicable) with not less than 45 days’ notice prior to commencement of any audit. 
  

	 	d.	Emulsion Supply Agreement. As a condition precedent to, and in partial consideration to the Vendor for the sale of assets to the Purchaser set out in Section 2.1 of this Agreement, the Purchaser shall enter
into the ”Supply Agreement. 

 ARTICLE IV 

PROSECUTION, MAINTENANCE, AND ENFORCEMENT OF INTELLECTUAL PROPERTY 

Section 4.1 Prosecution and Maintenance of Intellectual Property. The Purchaser may, at its own expense, register, file,
prosecute, and maintain the Intellectual Property of the Omega Infusion Assets set forth in Schedule A in any jurisdiction(s) it so wishes, in its sole discretion. The Vendor shall at all times use reasonable commercial efforts to assist the
Purchaser with the filing, prosecution, and maintenance of the Intellectual Property to the extent reasonably required by the Purchaser from time to time, provided the Purchaser pays the Vendor’s reasonable out of pocket expenses of such
assistance. 
 Section 4.2 Enforcement of Intellectual Property. 

 

	 	a.	Notice of Infringement. Until payment of the Transaction Based Compensation, the Vendor shall notify the Purchaser in writing within thirty (30) business days of the Vendor becoming aware of any known
or alleged infringement(s) of such Intellectual Property, and shall concurrently provide the Purchaser with any evidence of such infringement(s). 

  

	 	b.	 Enforcement of the Intellectual Property. the Purchaser shall have the sole right, but not the obligation, to enforce any of such
Intellectual Property against any third party. Until payment of the Transaction Based Compensation the Vendor agrees to join as a party plaintiff in any such action initiated by the Purchaser if reasonably requested by the Purchaser, at the sole
cost of the Purchaser, and until payment of the Transaction Based Compensation, the Vendor shall use reasonable commercial efforts to assist the Purchaser as reasonably requested by the Purchaser from time to time at the Purchaser’s sole
expense. All proceeds or other consideration (net of legal fees, lost business profits and documented 

  
 6 

	 	
expenses incurred by or on behalf of the Purchaser) received as a result of the Purchaser’s prosecuting such infringement claim shall be divided by and between the Parties with eighty five
(85%) due to Purchaser and fifteen percent (15%) due to Vendor. The Purchaser shall be entitled to settle or resolve any infringement claim relating to the Intellectual Property without the consent of the Vendor. 

Section 4.3 Further Assurances. On a continuing basis until payment of the Transaction Based Compensation resulting from a
disposition of all or substantially all of the Omega Infusion Assets, the Vendor will make, execute, acknowledge, deliver, file and record, as the case may be, with the proper filing and recording agencies in any jurisdiction, all such instruments,
and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by the Purchaser, to carry out the intent and purposes of this Agreement, provided that the Purchaser shall pay Vendor’s reasonable out of
pocket expenses of such action. 
 Section 4.4 Protection of Formulae. Vendor shall at all times until payment of the
Transaction Based Compensation use its reasonable commercial efforts to protect and preserve the security, confidentiality and value of the Formulae, and other confidential information related thereto. Without limiting the foregoing, the Vendor
shall not disclose the contents of the Formulae except to those with a need to know basis for the purposes of fulfilling its obligations under this Agreement or the Supply Agreement, and provided that recipients of such disclosure have agreed in
writing to perpetually maintain the confidentiality of such information. 
 ARTICLE V 

REPRESENTATIONS AND WARRANTIES 

Section 5.1 Vendor Representations and Warranties. The Vendor, as of the date hereof, represents and warrants to the
Purchaser and acknowledges that the Purchaser is relying upon such representations and warranties, in connection with the execution, delivery and performance of this Agreement, notwithstanding any investigation made by or on behalf of the Purchaser,
as follows: 
  

	 	a.	Organization and Good Standing. The Vendor is a company duly organized, validly existing and in good standing under the laws of the State of New York and has the requisite corporate power and authority to
own, lease and to carry on its business as now being conducted. 

  

	 	b.	Authority. The Vendor has all necessary legal power, capacity and authority to enter into the documents, instruments (the “Vendor Documents”) and perform its obligations in connection and
under this Agreement and the consummation of the transactions contemplated hereunder. The execution and delivery of each of the Vendor Documents by the Vendor and the consummation of the transactions contemplated hereby have been duly authorized by
the Vendor’s board of directors. No other corporate or shareholder proceeding on the part of the Vendor is necessary to authorize such documents or to consummate the transactions contemplated hereby. This Agreement has been, and the other
Vendor Documents when executed and delivered by the Vendor as contemplated by this Agreement will be, duly executed and delivered by the Vendor and this Agreement is, and the other Vendor Documents when executed and delivered by the Vendor as
contemplated hereby will be, valid and binding obligations of the Vendor enforceable in accordance with their respective terms except: 

  
 7 

	 	i.	as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally; 

 

	 	ii.	as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies; and 

  

	 	iii.	as limited by public policy. 

  

	 	c.	Non-Contravention. Neither the execution, delivery and performance of this Agreement, nor the consummation of the Transaction, will: 

 

	 	i.	conflict with, result in a violation of, cause a default under (with or without notice, lapse of time or both) or give rise to a right of termination, amendment, cancellation or acceleration of any obligation contained
in or the loss of any material benefit under, or result in the creation of any lien, security interest, charge or encumbrance upon any of the Omega Infusion Assets, the Vendor or any of its subsidiaries under any term, condition or provision of any
loan or credit agreement, note, debenture, bond, mortgage, indenture, lease or other agreement, instrument, permit, license, judgment, order, decree, statute, law, ordinance, rule or regulation applicable to the Omega Infusion Business, Vendor or
any of its subsidiaries, or any of their respective material property or assets; 

  

	 	ii.	violate any provision of the Articles, Bylaws or any other documents of the Vendor, any of their respective subsidiaries or any applicable laws; or 

 

	 	iii.	violate any order, writ, injunction, decree, statute, rule, or regulation of any court or governmental or regulatory authority applicable to the Vendor, any of their respective subsidiaries or any of their respective
material property or assets. 

  

	 	d.	Actions and Proceedings. The Vendor has not received any oral or written claim or cease and desist letter, and is not subject to any threatened, pending or outstanding action, suit, claim, demand,
injunction, judgment, order, decree, ruling, charge, settlement, or other dispute involving any Third Party Intellectual Property related to the Omega Infusion Assets, and there are no grounds for any claim: (i) alleging that the Omega Infusion
Assets infringes upon or misappropriates any Third Party Intellectual Property; or (ii) challenging the title, inventoryship, validity, enforceability, or alleging misuse, of the Omega Infusion Assets. 

 

	 	e.	Filing, Consents and Approvals. No filing or registration with, no notice to and no permit, authorization, consent, or approval of any public or governmental body or authority or other Person is necessary
for the consummation by the Vendor of the Transaction contemplated by this Agreement or to enable the Purchaser to continue to conduct the Omega Infusion Business after the Closing Date in a manner which is consistent with that in which the business
is presently conducted. 

  

	 	f.	 Title to the Omega Infusion Assets. Except to the extent that such materials are non-proprietary and in the public domain, the Vendor
has sole and full legal right, power and authority to sell, assign and transfer the Omega Infusion Assets free and clear from any and all liens, security interests, mortgages, charges, claims, encumbrances or other restrictions on title or
transferability of any kind, and are not subject to divestment or rescission for any 

  
 8 

	 	
reason or cause to the Purchaser in accordance with the terms of this Agreement and to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby and there
exists no agreement to create any lien, security interest, mortgage, charge, claim, encumbrance or other restriction on title or transferability of any kind over any of the Omega Infusion Assets. 

 

	 	g.	The Vendor has not granted to any third party any right or license: 

  

	 	i.	to file, prosecute, maintain, and defend any Patent or trademark in respect the Omega Infusion Assets, or any improvements thereupon; 

 

	 	ii.	to reproduce, make, have made, use, import, export, sell, lease or otherwise exploit any products based on the Omega Infusion Assets or any components thereof; 

 

	 	iii.	to provide or sell any service based upon or incorporating the Omega Infusion Assets; 

  

	 	iv.	to copy, translate or modify any copyright works relating to the Omega Infusion Assets; 

  

	 	v.	to otherwise practice or exploit the Omega Infusion Assets; 

  

	 	vi.	to make, practice or exploit any derivative works, improvements or other variations derived from or related to the Omega Infusion Assets; and 

 

	 	vii.	to assign, gift, sell, license, cross-license or otherwise dispose of any or all of the rights granted to the Purchaser hereunder to any person or entity. 

 

	 	h.	Intellectual Property and Know-How Necessary for the Business. Except as set forth in Schedule “B” hereto, all former and current employees and contractors of the Vendor have executed written
contracts, agreements or other undertakings with the Vendor that assign all rights to any inventions, improvements, discoveries, or information relating to the Omega Infusion Assets of the Vendor. (No employee, director, officer or shareholder of
the Vendor owns directly or indirectly in whole or in part, any Omega Infusion Asset. To the best knowledge of the Vendor, no employee or contractor of the Vendor has entered into any contract or agreement that requires the employee to transfer,
assign, or disclose information concerning the employee’s work to anyone other than the Vendor. 

  

	 	i.	Employees and Consultants. To the knowledge of the Vendor, no employee of the Vendor is in violation of any term of any employment contract, non-disclosure agreement, non-competition agreement or any other
contract or agreement relating to the Omega Infusion Assets. To the knowledge of the Vendor, no employee or consultant in its employ, or affiliate, associate or Person of any kind with which the Vendor has had a commercial relationship has used the
Omega Infusion Assets other than in the course of that party’s work for the Vendor. 

  

	 	j.	Material Contracts and Transactions. There is no material contract, agreement, license, permit, arrangement, commitment, instrument or contract relating to the Omega Infusion Assets to which the Vendor is
a party (each, a “Contract”). 

  
 9 

	 	k.	Assertion of Rights. The Vendor has not asserted any claim of infringement, misappropriation or misuse by any third party in respect of the Formulae or the other Omega Infusion Assets and, to the the
knowledge of the Vendor, there are no grounds for any such claims. 

  

	 	l.	Preservation. To the Vendor’s knowledge, there have been no disclosures of the Formulae to third parties without a confidentiality agreement. The Vendor has not applied for any Patents for the Omega
Infusion Assets. The Vendor has taken all reasonable measures to protect and preserve the security, confidentiality and value of the Omega Infusion Assets, including without limitation all trade secrets and other confidential information
constituting a part thereof. 

 Section 5.2 Purchaser Representations and Warranties. The Purchaser, as of
the date hereof, represents and warrants to the Vendor and acknowledges that the Vendor is relying upon such representations and warranties, in connection with the execution, delivery and performance of this Agreement, notwithstanding any
investigation made by or on behalf of the Vendor, as follows: 
  

	 	a.	Organization and Good Standing. The Purchaser is duly incorporated, organized, validly existing and in good standing under the laws of the State of Nevada and has all requisite corporate power and
authority to own, lease and to carry on its business as now being conducted. The Purchaser is qualified to do business and is in good standing as a foreign corporation in each of the jurisdictions in which it owns property, leases property, does
business, or is otherwise required to do so, where the failure to be so qualified would have a material adverse effect on the businesses, operations, or financial condition of the Purchaser. 

 

	 	b.	Authority. The Purchaser has all necessary legal power to enter into the documents, instruments (the “Purchaser Documents”) and perform its obligations under this Agreement and has taken
all necessary corporate action under the laws of the jurisdiction of its incorporation and its certificate of incorporation and bylaws to authorize the execution of this Agreement and the consummation of the transactions contemplated hereunder. The
execution and delivery of each of the Purchaser Documents by the Purchaser and the consummation by the Purchaser of the transactions contemplated hereby have been duly authorized by its board of directors and no other corporate or shareholder
proceedings on the part of the Purchaser is necessary to authorize such documents or to consummate the transactions contemplated hereby. This Agreement has been, and the other Purchaser Documents when executed and delivered by the Purchaser as
contemplated by this Agreement will be, duly executed and delivered by the Purchaser and this Agreement is, and the other Purchaser Documents when executed and delivered by the Purchaser as contemplated hereby will be, valid and binding obligations
of the Purchaser enforceable in accordance with their respective terms, except: 

  

	 	i.	as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally; 

 

	 	ii.	as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies; and 

  

	 	iii.	as limited by public policy. 

  
 10 

	 	c.	Non-Contravention. Neither the execution, delivery and performance of this Agreement, nor the consummation of the Transaction, will: 

 

	 	i.	conflict with, result in a violation of, cause a default under (with or without notice, lapse of time or both) or give rise to a right of termination, amendment, cancellation or acceleration of any obligation contained
in or the loss of any material benefit under, or result in the creation of any lien, security interest, charge or encumbrance upon any of the material properties or assets of the Purchaser under any term, condition or provision of any loan or credit
agreement, note, debenture, bond, mortgage, indenture, lease or other agreement, instrument, permit, license, judgment, order, decree, statute, law, ordinance, rule or regulation applicable to the Purchaser or any of its material property or assets;

  

	 	ii.	violate any provision of the applicable incorporation or charter documents of the Purchaser; or 

  

	 	iii.	violate any order, writ, injunction, decree, statute, rule, or regulation of any court or governmental or regulatory authority applicable to the Purchaser or any of its material property or assets. 

 

	 	d.	Actions and Proceedings. To the best knowledge of the Purchaser, there is no claim, charge, arbitration, grievance, action, suit, investigation or proceeding by or before any court, arbiter, administrative
agency or other governmental authority now pending or, to the best knowledge of the Purchaser, threatened against the Purchaser which involves any of the business, or the properties or assets of the Purchaser that, if adversely resolved or
determined, would have a material adverse effect on the business, operations, assets, properties, prospects or conditions of the Purchaser taken as a whole (a “Purchaser Material Adverse Effect”). There is no reasonable basis for
any claim or action that, based upon the likelihood of its being asserted and its success if asserted, would have such a Purchaser Material Adverse Effect. 

Section 5.3 Disclaimer. It is the explicit intent and understand of each Party that neither the Vendor nor any of
Vendor’s Affiliates is making any representation or warranty whatsoever, oral or written, express or implied, other than those set forth in this Agreement. Except for the representations and warranties specifically set forth in this Agreement,
the Omega Infusion Assets are being sold “as is” and “where is”. The express terms of this Agreement are in lieu of warranties, conditions, undertakings, terms and obligations implied statute, case law, trade usage, course of
dealing or otherwise all of which are excluded to the fullest extent permitted by law. Without limiting the foregoing, except as set forth in this Article V, the Parties expressly disclaim all other representations and warranties of any kind or
nature, express or implied, including, without limitation, any relating to merchantability and fitness for a particular purpose, or any relating to the financial condition, results of operations, assets or liabilities of Vendor. Further Vendor makes
no representation, warranty or covenant of any kind with respect to any projections, estimates or budgets heretofore delivered to or made available to Purchaser or its Affiliates, or their respective auditors or other agents or representatives of
future revenues, expenses, expenditures, future results of operations (or any component thereof), future cash flows or future financial condition (or any component thereof) of Vendor, the Omega Infusion Assets, the former Omega Infusion Business, or
future business and operations. 

  
 11 

 ARTICLE VI 

INDEMNIFICATION 

Section 6.1 Indemnity of the Vendor. The Vendor and its Affiliates will indemnify and hold harmless the Purchaser and each
and all of its directors, officers, employees, agents, Affiliates, successors and assigns, together with each and all of their respective directors, officers, employees, agents, successors and assigns (each and all of the foregoing being referred to
collectively as the “Purchaser Indemnitees”) from and against any and all claims, losses, liabilities, damages, costs, obligations, assessments, penalties and interest, demands, actions, and expenses (including actual
attorneys’ fees), whether direct or indirect, known or unknown, absolute or contingent, including, without limitation, settlement costs and any legal, accounting, and other expenses for investigation or defending any actions or threatened
actions (collectively, “Loss”) which Purchaser Indemnitees may suffer or incur by reason of any misrepresentation, or non-fulfilment of any covenant, on the part of the Vendor under this
Agreement, or from any misrepresentation in, or omission from, any certificate, or other instrument, furnished, or to be furnished, to the Purchaser in relation to this Agreement. 

Section 6.2 Indemnity of the Purchaser. The Purchaser and its Affiliates will indemnify and hold harmless the Vendor and
all of its directors, officers, employees, agents, Affiliates, successors and assigns, together with each and all of their respective directors, officers, employees, agents, successors and assigns ( each and all of the foregoing being referred to
collectively as the “Vendor Indemnitees”) from and against any and all Loss which the Vendor Indemnitees may suffer or incur by reason of any misrepresentation, or non-fulfilment of any
covenant, on the part of the Purchaser under this Agreement, or from any misrepresentation in, or omission from, any certificate, or other instrument, furnished, or to be furnished, to the Vendor in relation to this Agreement. 

Section 6.3 Indemnification Procedures. 
  

	 	a.	The Party seeking indemnification (the “Indemnified Party”) pursuant to this Article VI shall promptly notify the indemnifying party (the “Indemnifying Party”), in writing, of such
claim describing such claim in reasonable detail; provided, however, that the failure to provide such notice shall not affect the obligations of the Indemnifying Party unless and only to the extent it is actually prejudiced thereby.

  

	 	b.	The Indemnifying Party shall have the right within thirty (30) days after receipt of such notice to take control, through counsel of its own choosing (but reasonably acceptable to the Indemnified Party) and at its
own cost and expense, the settlement, or defense thereof unless: (i) the Indemnifying Party is also a party to the proceeding and the Indemnified Party determines in good faith that joint representation would be inappropriate; or (ii) the
Indemnifying Party fails to provide reasonable assurance to the Indemnified Party of its financial capacity to defend such proceeding, and provide indemnification with respect thereto. The Indemnifying Party shall not, without the written consent of
the Indemnified Party (which consent shall not be unreasonably withheld, delayed, or conditioned), settle or compromise any action, unless such settlement or compromise includes an unconditional release of the Indemnified Party. If the Indemnifying
Party does not notify the Indemnified Party within thirty (30) days after the receipt of notice of a claim of indemnity hereunder that it elects to undertake the defense thereof, the Indemnified Party shall have the right to contest, settle, or
compromise the claim but shall not pay or settle any such claim without the consent of the Indemnifying Party (which consent shall not be unreasonably withheld, delayed, or conditioned). 

  
 12 

	 	c.	The Indemnifying Party and the Indemnified Party shall cooperate fully in all aspects of any investigation, defense, pre-trial activities, trial, compromise, settlement, or discharge of any claim in respect of which
indemnity is sought pursuant to this Article VI, including, without limitation, providing the other Party with reasonable access to employees and officers (including as witnesses) and other information. The remedies provided in this Article VI shall
not be exclusive of or limit any other remedies that may be available to the Indemnified Parties. 

  

	 	d.	No Party shall be entitled to indemnification from the other Party for any Loss arising out of relating to the willful misconduct, gross negligence or bad faith of the Party seeking indemnification. 

Section 6.4 Notwithstanding anything in this Agreement to the contrary, neither Party shall be liable to the other Party for any
indirect, special, incidental, or consequential damages of any kind or type including, without limitation, loss of revenue, profits, use, savings or economic advantage or opportunity. 

Section 6.5 The total liability of Vendor under or arising out of this Agreement shall not exceed the amount of the Transaction Based
Compensation. 
 ARTICLE VII 

CONFIDENTIAL INFORMATION 

Section 7.1 Confidentiality. The Vendor agrees that, as of the Effective Date, all Confidential Information shall remain
the exclusive property of the Purchaser. Accordingly, the Vendor agrees not to disclose any Confidential Information and to maintain such Confidential Information in strictest confidence, to take all reasonable precautions to prevent its
unauthorized dissemination and to refrain from sharing any of the Confidential Information with any third party (i) except those with a “need to know” and solely in connection with the permitted uses by the Vendor (as applicable) of
the Confidential Information; or (ii) except as required by court order or other legal process; or (iii) except as may be publicly disclosed or come into the public domain through no fault of the Vendor. The Vendor expressly acknowledges
that in the event of a breach by them of any terms of this Agreement, the Purchaser will be caused irreparable injury which cannot be adequately compensated by money damages. Accordingly, the Purchaser shall be entitled to obtain injunctive relief,
in addition to any other rights or remedies which the Purchaser may have, to enforce the terms of this Agreement and prevent disclosure of Confidential Information. 

ARTICLE VIII 
 TERM AND
TERMINATION 
 Section 8.1 Term. This Agreement shall commence on the Effective Date and shall continue in
perpetuity, provided, however, that the representations and warranties of the Vendor are given and effective on the Closing Date, and are not intended to survive or be continuing representations and warranties thereafter. Notwithstanding anything in
this Agreement to the contrary, any action, suit or proceeding thereon that may be commenced Purchaser against Vendor shall be limited to a period of three (3) years from the Closing Date. 

Section 8.2 Waiver. The failure of either Party to exercise any rights or remedies to which it is entitled shall not be
deemed to be a waiver of or otherwise affect, impair, or prevent the non-breaching Party from exercising any rights or remedies to which it may be entitled, arising either from the happening of any such event, or as a result of the subsequent
happening of the same or any other event or events provided forth herein. 

  
 13 

 ARTICLE IX 

CLOSING 

Section 9.1 Closing. The Closing shall take place on the Closing Date at such location as agreed to by the Parties.

 Section 9.2 Closing Deliveries of the Vendor. At Closing, the Vendor shall deliver or cause to be delivered the
following, fully executed and in the form and substance reasonably satisfactory to the Purchaser: 
  

	 	a.	copies of all resolutions and/or consent actions adopted by or on behalf of the board of directors of the Vendor evidencing approval of this Agreement and the Transaction; 

 

	 	b.	any legally necessary documents to complete the transactions hereby, each duly executed by the Vendor, as required to give effect to the Transaction; 

 

	 	c.	the resolutions required to effect the changes contemplated in this Agreement; and 

Section 9.3 Closing Deliveries of the Purchaser. At Closing, the Purchaser shall deliver or cause to be delivered the
following, fully executed and in the form and substance reasonably satisfactory to the Vendor: 
  

	 	a.	copies of all resolutions and/or consent actions adopted by or on behalf of the board of directors of the Purchaser evidencing approval of this Agreement and the Transaction; and 

 

	 	b.	any legally necessary documents to complete the transactions contemplated hereby, each duly executed by the Purchaser, as required to give effect to the Transaction. 

Section 9.4 Financial Statement Requirements. The Vendor acknowledges that the Purchaser is a public reporting company in
the United States and, as a result of the Transaction, will be required to prepare and file with the Securities and Exchange Commission financial statements pursuant to Rule 3-05 of Regulation S-X and pro forma financial information pursuant to
Article 11 of Regulation S-X (the “Financial Statements”). Accordingly, between the execution of this Agreement and the Closing Date, the Vendor agrees to promptly provide to the Purchaser all information concerning the Omega
Infusion Business and Omega Infusion Assets reasonably requested by the Purchaser in order to prepare the requisite financial statements and information. 

Section 9.5 Closing Date. The Closing Date shall be a date mutually agreed upon by the Parties in writing and which shall,
in any event, follow and be subject to the prior completion of the Financial Statements. 
 ARTICLE X 

GENERAL PROVISIONS 

Section 10.1 Independent Contractor. The relationship of the Parties is that of independent contractors. Neither Party nor
any of their respective employees, agents or contractors shall by reason of this Agreement be deemed an employee, agent or joint venture of the other Party. 

  
 14 

 Section 10.2 Notices. All notices required or permitted hereunder must be made
in writing, in the English language, and will be deemed to be delivered and received (i) if personally delivered or if delivered by telex, telegram, facsimile or courier service, when actually received by the Party to whom notice is sent, or
(ii) if delivered by mail (whether actually received or not), at the close of business on the third business day next following the day when placed in the mail, postage prepaid, certified or registered, addressed to the appropriate Party or
Parties, at the address of such Party or Parties set forth above (or at such other address as such Party may designate by written notice to all other Parties in accordance herewith). 

Section 10.3 Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of
New York without regard to the conflicts of law provisions thereof. The Parties hereby agree to the exclusive subject matter and personal jurisdiction of the federal and state courts located in the city of New York, New York for all matters arising
from this Agreement and hereby irrevocably waive any defense of inconvenient forum or similar defenses. 
 Section 10.4
Severability. If any provision of this Agreement is held invalid, illegal or unenforceable, such provision shall be reformed only to the extent necessary to effect the original intentions of the Parties, and all remaining provisions
shall continue in full force and effect. 
 Section 10.5 Assignment. This Agreement may be assigned by the Purchaser in
its sole discretion. This Agreement may not be assigned by the Vendor and attempted assignment or delegation of this Agreement by the Vendor without the written approval of the Purchaser shall be void. 

Section 10.6 Force Majeure. Neither Party shall be liable hereunder by reason of any failure or delay in the performance of
its obligations hereunder (except for the payment of money) on account of strikes, shortages, riots, insurrection, fires, flood, storm, explosions, acts of God, war, governmental action, labor conditions, earthquakes or any other cause which is
beyond the reasonable control of such Party. 
 Section 10.7 Advice of Counsel; Expenses. Each Party has been advised,
and is hereby advised, to seek the representation of separate and independent counsel for the transactions contemplated herein prior to executing this Agreement. Each Party shall pay its own costs and expenses involved with or arising out of
Purchaser’s investigation of the Omega Infusion Assets, and the negotiation and execution of this Agreement and the Transaction. 

Section 10.8 Further Assurances. Each Party agrees to do and perform or cause to be done and performed all such further
acts and to execute and deliver all such other agreements, certificates, instruments and documents as any other Party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation
of the transactions contemplated hereby. 
 Section 10.9 Binding Effect. This Agreement shall enure to the benefit of,
and be binding upon, the Parties hereto and their respective heirs, executors and successors. 
 Section 10.10
Modification. Any modification or amendment of this Agreement will be effective only if it is in writing and signed by the Vendor and the Purchaser. 

Section 10.11 Construction. The captions and titles of the articles, sections and subsections of this Agreement are for
convenience of reference only and are not to be considered in construing this Agreement. No Party, nor its respective counsel, shall be deemed the drafter of this Agreement for purposes of construing this Agreement, and all language in all parts of
this Agreement shall be construed simply and in accordance with its fair meaning, and not strictly for or against any Party. 

  
 15 

 Section 10.12 Counterparts. This Agreement may be executed in one or more
counterparts (including by facsimile or emailed PDF), each of which, shall be deemed to be an original, but all of which together shall constitute one and the same instrument. 

Section 10.13 Entire Agreement; No Third Party Beneficiary. This Agreement together with any attachments, schedules and
exhibits, constitute the entire agreement of the Parties with respect to the subject matter of this Agreement. This Agreement supersedes any and all agreements, whether oral or written, between the Parties to this Agreement with respect to the
subject of this Agreement. Except as otherwise expressly provided herein, this Agreement may be modified only by a writing signed by an authorized representative of each Party. Nothing in this Agreement, express or implied, is intended to confer
upon any other Person any right or remedy under or by reason of this Agreement, nor shall this Agreement confer any such third party right or remedy. 
 IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized agents as of the day and year first above written. 
  

	
	OMEGA BRANDS INC.
	
	 /s/ Jim Dickson

	Per: Jim Dickson, CEO and President
	
	MCT BEVERAGE COMPANY, LLC
	
	 /s/ Frank Gallagi

	Per: Frank Gallagi, CFO
	
	 MYCELL TECHNOLOGIES LLC

	
	 /s/ Frank Gallagi

	Per: Frank Gallagi, CFO

  
 16 

 SCHEDULE “A” 

OMEGA INFUSION ASSETS 
  

																	
	 	  	 Identification of Asset:
	  	 Brief Description of Asset:

	1.	  	Omega Infusion Enhanced Water	  	Brand/Trademark
	2.	  	Omega Infusion Enhanced Water:	  	Mixing Formula
	3.	  	Omega Infusion Shot	  	Brand/Trademark
	4.	  	Omega Infusion Shot	  	Mixing Formula
	5.	  	Omega Infusion	  	Trademark
	6.	  	Omega Infusion	  	
		  		  	URL’s
	 	  	           Domain Name
	  	TLD	  	Exp. Date	  	Status	  	Privacy	  	Locked	  	Auto Renew	  	 
									
		  	 BUYOMEGAINFUSION.COM
	  	.com	  	03/13/15	  	Active	  	Public	  	Locked	  	On	  	
									
		  	 DRINKOMEGAINFUSION.COM
	  	.com	  	06/06/14	  	Active	  	Public	  	Locked	  	On	  	
									
		  	 OMEGAINFUSED.COM
	  	.com	  	06/06/15	  	Active	  	Public	  	Locked	  	On	  	
									
		  	 OMEGAINFUSED.INFO
	  	.info	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSED.NET
	  	.net	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSED.ORG
	  	.org	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSION.COM
	  	.com	  	06/06/15	  	Active	  	Public	  	Locked	  	On	  	
									
		  	 OMEGAINFUSIONDRINKS.COM
	  	.com	  	06/06/15	  	Active	  	Public	  	Locked	  	On	  	
									
		  	 OMEGAINFUSIONDRINKS.INFO
	  	.info	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSIONDRINKS.NET
	  	.net	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSIONDRINKS.ORG
	  	.org	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSIONONLINE.COM
	  	.com	  	03/13/15	  	Active	  	Public	  	Locked	  	On	  	
									
		  	 OMEGAINFUSIONSHOTS.COM
	  	.com	  	06/06/15	  	Active	  	Public	  	Locked	  	On	  	
									
		  	 OMEGAINFUSIONSHOTS.INFO
	  	.info	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSIONSHOTS.NET
	  	.net	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSIONSHOTS.ORG
	  	.org	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSIONWATER.COM
	  	.com	  	06/06/15	  	Active	  	Public	  	Locked	  	On	  	
									
		  	 OMEGAINFUSIONWATER.INFO
	  	.info	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSIONWATER.NET
	  	.net	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
									
		  	 OMEGAINFUSIONWATER.ORG
	  	.org	  	05/28/14	  	Active	  	Public	  	Locked	  	Off	  	
		
	URL’s managed by GoDaddy.com	  	

  

  
 17 

 SCHEDULE “B” 

EMULSION SUPPLY AND FORMULATION SERVICES AGREEMENT 

  
 18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]